TICKERNERD
Menu
BBOTBBOTHealthcare · Biotechnology

BBOT Stock Forecast: Bridgebio Oncology Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$5.05
+2.02% on the day

The 12 Wall Street analysts covering Bridgebio Oncology Therapeutics, Inc. hold a median 12-month price target of $22 — +335.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$396.9M
Ticker Nerd rank
9 / 100
Median analyst target
$22
Analysts covering
12
Revenue$0.0
Operating income−$60.2M
Net income−$56.5M
Free cash flow−$44.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−43.8%
1M
−44.3%
YTD
−59.7%
1Y
−51.4%
From 52W high
−63.2%
From 52W low
+2.0%
$5
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBOT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bridgebio Oncology Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
9 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
59
Size
56
Quality
41
Value
35
Accruals
27
Revisions
26
Momentum
24
Issuance
13
Growth
8

Volatility (59): The share price has been relatively steady.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BBOT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBOT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26BBOTHigh $50Median $22Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $15Median $22High $50

The green dot is the last close — the median target sits +335.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
11 Sept 2026JP MorganMaintainsOverweight$25 → $23
10 Sept 2026Leerink PartnersMaintainsOutperform$39 → $27
9 Sept 2026Canaccord GenuityMaintainsBuy$23 → $20
9 Sept 2026Raymond JamesMaintainsOutperform$24 → $22
9 Sept 2026StifelMaintainsBuy$23 → $15
9 Sept 2026WedbushReiteratesOutperform$25
14 Aug 2026JP MorganMaintainsOverweight$27 → $25
14 Aug 2026JP MorganMaintainsOverweight—
8 July 2026JP MorganInitiatesOverweight$27
8 July 2026JP MorganInitiatesOverweight—
22 June 2026OppenheimerAssumesOutperform$22
11 May 2026Canaccord GenuityInitiatesBuy—
6 Mar 2026HC Wainwright & Co.MaintainsBuy—
11 Feb 2026StifelInitiatesBuy—
9 Jan 2026Raymond JamesInitiatesOutperform—
11 Dec 2025WedbushReiteratesOutperform—
5 Dec 2025Morgan StanleyInitiatesOverweight—
25 Nov 2025WedbushReiteratesOutperform—
13 Nov 2025OppenheimerMaintainsOutperform—
17 Sept 2025Leerink PartnersInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBOT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BBOT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Bridgebio Oncology Therapeutics, Inc. returned −51.4% against +17.5% for the S&P 500, dividends included.

BBOT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Oct 25Jan 26Apr 26Jul 26BBOTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BBOT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
9
Fundamentals

Bridgebio Oncology Therapeutics, Inc. (BBOT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 66% of US stocks

EV / EBITDA
−0.9×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.9%

Higher than 15% of US stocks

Return on assets
−47.1%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bridgebio Oncology Therapeutics, Inc. (BBOT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bridgebio Oncology Therapeutics, Inc. has a market value of $396.9M and an enterprise value of $173.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$182.1M.

  • Diluted earnings per share, trailing twelve months: $−1,232.83.

  • Free cash flow in the twelve months to 30 June 2026: −$151.6M.

  • Shares outstanding: 80.1M.

  • Trailing P/E: −1.2×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Bridgebio Oncology Therapeutics, Inc. employs 88 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

BBOT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BBOTBridgebio Oncology Therapeutics, Inc.$396.9M
9
GALTGalectin Therapeutics, Inc.$394.3M
70
RZLTRezolute, Inc.$403.8M
33
BNTCBenitec Biopharma, Inc.$410.3M
42
LRMRLarimar Therapeutics, Inc.$413.9M
30
EDITEditas Medicine, Inc.$414.3M
78
EVMNEvommune, Inc.$379.6M
10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bridgebio Oncology Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BBOT news & analysis

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

GlobeNewsWire · 8 Sept 2026positive

BBOT announced new clinical data for its KRASG12C inhibitor BBO-8520 and outlined a strategic prioritization of BBO-8520 combined with a checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced NSCLC patients, as well as BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers.

Why it matters — The announcement signals BBOT's focus on its RAS-pathway oncology pipeline and combination strategies, which are central to its near-term clinical development direction.

BBOT to Participate in Upcoming Investor Healthcare Conferences

GlobeNewsWire · 1 Sept 2026neutral

BridgeBio Oncology Therapeutics, Inc. (BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, announced that members of its leadership team will participate in upcoming investor healthcare conferences.

Why it matters — BBOT watchers may gain new insight into the company's progress and strategy as its leadership presents at these investor conferences.

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 11 Aug 2026neutral

BridgeBio Oncology Therapeutics announced on August 11, 2026 that it awarded inducement grants on August 10, 2026 under its 2025 Inducement Plan, as a material inducement for the employment of two individuals hired by the company in July 2026. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — A BBOT watcher would care because the inducement grants signal the company is attracting and onboarding new talent as it advances its clinical-stage RAS-pathway oncology programs.

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

GlobeNewsWire · 11 Aug 2026positive

BBOT reported its second quarter 2026 financial results and provided a business update, noting continued advancement of monotherapy and combination cohorts across its clinical programs. The company initiated dosing of BBO-11818 in combination with cetuximab and, after quarter end, in combination with BBO-10203, presented preclinical data at AACR, and stated its cash runway is expected to fund operations into 2028.

Why it matters — The update signals continued clinical progress, a longer cash runway into 2028, and new combination dosing milestones for BBOT's RAS-pathway programs.

FAQ

Frequently asked questions about BBOT stock

What is the BBOT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Bridgebio Oncology Therapeutics, Inc. have a median 12-month price target of $22, with estimates ranging from $15 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BBOT stock a buy right now?

Of the 12 analysts covering Bridgebio Oncology Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bridgebio Oncology Therapeutics, Inc. 9 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BBOT?

As at 12 Sept 2026, Bridgebio Oncology Therapeutics, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (59 of 100).

Will BBOT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +335.6% from the last close, and Ticker Nerd's factor model ranks Bridgebio Oncology Therapeutics, Inc. 9 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BBOT stock forecast for 2030?

No analyst covering Bridgebio Oncology Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBOT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $50 over the next 12 months.

How has BBOT stock performed over the past year?

Bridgebio Oncology Therapeutics, Inc. returned -51.4% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bridgebio Oncology Therapeutics, Inc. do?

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancers driven by RAS and PI3Kα pathway alterations.

What is the latest news on BBOT?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers". BBOT announced new clinical data for its KRASG12C inhibitor BBO-8520 and outlined a strategic prioritization of BBO-8520 combined with a checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced NSCLC patients, as well as BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers.

Company

About Bridgebio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancers driven by RAS and PI3Kα pathway alterations. BridgeBio Oncology Therapeutics designs oral, targeted oncology candidates intended to address some of the most common cancer-driving mutations, with a pipeline centered on RAS-related programs and precision cancer treatment. Its current work includes advancing investigational medicines that aim to inhibit KRAS and related signaling mechanisms, supporting the broader shift toward mutation-specific cancer care. Headquartered in South San Francisco, California, BridgeBio Oncology Therapeutics plays a specialized role in the oncology market by concentrating on difficult-to-target molecular pathways that are relevant across multiple solid tumors.

CEO Mr. Eli M. Wallace Ph.D. · 88 employees · United States · https://bbotx.com